|
1
|
Tormo E, Adam-Artigues A, Ballester S,
Pineda B, Zazo S, González-Alonso P, Albanell J, Rovira A, Rojo F,
Lluch A and Eroles P: The role of miR-26a and miR-30b in
HER2+ breast cancer trastuzumab resistance and
regulation of the CCNE2 gene. Sci Rep. 7:413092017. View Article : Google Scholar
|
|
2
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merino Bonilla JA, Torres Tabanera M and
Ros Mendoza LH: Breast cancer in the 21st century: From early
detection to new therapies. Radiologia. 59:368–379. 2017.In
English, Spanish. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim YJ, Jung SY and Kim K: Survival
benefit of radiotherapy after surgery in de novo stage IV breast
cancer: A population-based propensity-score matched analysis. Sci
Rep. 9:85272019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen PL, Taghian AG, Katz MS, Niemierko
A, Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris JR:
Breast cancer subtype approximated by estrogen receptor,
progesterone receptor, and HER-2 is associated with local and
distant recurrence after breast-conserving therapy. J Clin Oncol.
26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chavez-Blanco A, Perez-Sanchez V,
Gonzalez-Fierro A, Vela-Chavez T, Candelaria M, Cetina L, Vidal S
and Dueñas-Gonzalez A: HER2 expression in cervical cancer as a
potential therapeutic target. BMC Cancer. 4:592004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Horton J: Trastuzumab use in breast
cancer: Clinical issues. Cancer Control. 9:499–507. 2002.
View Article : Google Scholar
|
|
9
|
Sarup JC, Johnson RM, King KL, Fendly BM,
Lipari MT, Napier MA, Ullrich A and Shepard HM: Characterization of
an anti-p185HER2 monoclonal antibody that stimulates receptor
function and inhibits tumor cell growth. Growth Regul. 1:72–82.
1991.PubMed/NCBI
|
|
10
|
Lane HA, Beuvink I, Motoyama AB, Daly JM,
Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation
through modulation of p27(Kip1)-Cdk2 complex formation: Receptor
overexpression does not determine growth dependency. Mol Cell Biol.
20:3210–3223. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petit AM, Rak J, Hung MC, Rockwell P,
Goldstein N, Fendly B and Kerbel RS: Neutralizing antibodies
against epidermal growth factor and ErbB-2/neu receptor tyrosine
kinases down-regulate vascular endothelial growth factor production
by tumor cells in vitro and in vivo: Angiogenic implications for
signal transduction therapy of solid tumors. Am J Pathol.
151:1523–1530. 1997.PubMed/NCBI
|
|
12
|
Sliwkowski MX, Lofgren JA, Lewis GD,
Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing
the mechanism of action of trastuzumab (Herceptin). Semin Oncol.
26:60–70. 1999.PubMed/NCBI
|
|
13
|
Van Swearingen AED, Siegel MB, Deal AM,
Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, et
al: LCCC 1025: A phase II study of everolimus, trastuzumab, and
vinorelbine to treat progressive HER2-positive breast cancer brain
metastases. Breast Cancer Res Treat. 171:637–648. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding K, Wu Z, Li X, Sheng Y, Wang X and
Tan S: LMO4 mediates trastuzumab resistance in HER2 positive breast
cancer cells. Am J Cancer Res. 8:594–609. 2018.PubMed/NCBI
|
|
15
|
Tan H, Huang S, Zhang Z, Qian X, Sun P and
Zhou X: Pan-Cancer analysis on microRNA-associated gene activation.
EBioMedicine. 43:82–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: Metazoan MicroRNAs. Cell.
173:20–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schneider A, Victoria B, Lopez YN,
Suchorska W, Barczak W, Sobecka A, Golusinski W, Masternak MM and
Golusinski P: Tissue and serum microRNA profile of oral squamous
cell carcinoma patients. Sci Rep. 8:6752018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Venturutti L, Cordo Russo RI, Rivas MA,
Mercogliano MF, Izzo F, Oakley RH, Pereyra MD, Proietti CJ,
Yankilevich P, Roa JC, et al: miR-16 mediates trastuzumab and
lapatinib response in ErbB-2-positive breast and gastric cancer via
its novel targets CCNJ and FUBP1. Oncogene. 35:6189–6202. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song W, Wu S, Wu Q, Zhou L, Yu L, Zhu B
and Gong X: The microRNA-141-3p/CDK8 pathway regulates the
chemosensitivity of breast cancer cells to trastuzumab. J Cell
Biochem. 120:14095–14106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noyan S, Gurdal H and Gur Dedeoglu B:
Involvement of miR-770-5p in trastuzumab response in HER2 positive
breast cancer cells. PLoS One. 14:e02158942019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Cola A, Volpe S, Budani MC, Ferracin M,
Lattanzio R, Turdo A, D'Agostino D, Capone E, Stassi G, Todaro M,
et al: miR-205-5p-mediated downregulation of ErbB/HER receptors in
breast cancer stem cells results in targeted therapy resistance.
Cell Death Dis. 6:e18232015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pu T, Shen M, Li S, Yang L, Gao H, Xiao L,
Zhong X, Zheng H, Liu Y, Ye F and Bu H: Repression of miR-135b-5p
promotes metastasis of early-stage breast cancer by regulating
downstream target SDCBP. Lab Invest. 99:1296–1308. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Xia F, Zhang F, Cui Y, Wang Q,
Liu H and Wu Y: miR-135b-5p enhances doxorubicin-sensitivity of
breast cancer cells through targeting anterior gradient 2. J Exp
Clin Cancer Res. 38:262019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
National Institutes of Health: Guide for
the Care and Use of Laboratory Animals. The National Academies
Press; Washington, DC: pp. p2462011
|
|
26
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH,
Glennie MJ, et al: Guidelines for the welfare and use of animals in
cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Le XF, Almeida MI, Mao W, Spizzo R, Rossi
S, Nicoloso MS, Zhang S, Wu Y, Calin GA and Bast RC Jr: Modulation
of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in
breast cancer. PLoS One. 7:e411702012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lulli V, Buccarelli M, Martini M, Signore
M, Biffoni M, Giannetti S, Morgante L, Marziali G, Ilari R,
Pagliuca A, et al: miR-135b suppresses tumorigenesis in
glioblastoma stem-like cells impairing proliferation, migration and
self-renewal. Oncotarget. 6:37241–37256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiao M, Cai J, Cai L, Jia J, Xie L, Zhu Y,
Huang B, Jin D and Wang Z: Let-7e sensitizes epithelial ovarian
cancer to cisplatin through repressing DNA double strand break
repair. J Ovarian Res. 10:242017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Krützfeldt J, Rajewsky N, Braich R, Rajeev
KG, Tuschl T, Manoharan M and Stoffel M: Silencing of microRNAs in
vivo with 'antagomirs'. Nature. 438:685–689. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang H, Song C, Ye F, Gao G, Ou X, Zhang L
and Xie X and Xie X: miR-200c suppresses stemness and increases
cellular sensitivity to trastuzumab in HER2+ breast
cancer. J Cell Mol Med. 23:8114–8127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Montagnoli A, Fiore F, Eytan E, Carrano
AC, Draetta GF, Hershko A and Pagano M: Ubiquitination of p27 is
regulated by Cdk-dependent phosphorylation and trimeric complex
formation. Genes Dev. 13:1181–1189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y,
Kong R, Luo Y, Shi Y, Wang K and Ji G: miR-206 is down-regulated in
breast cancer and inhibits cell proliferation through the
up-regulation of cyclinD2. Biochem Biophys Res Commun. 433:207–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vu T and Claret FX: Trastuzumab: Updated
mechanisms of action and resistance in breast cancer. Front Oncol.
2:622012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu WF, Wang HM, Lu BC, Zhang GZ, Ma HM and
Wu ZY: miR-206 inhibits human laryngeal squamous cell carcinoma
cell growth by regulation of cyclin D2. Eur Rev Med Pharmacol Sci.
19:2697–2702. 2015.
|
|
36
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: miR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting cyclin D2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pan JL, Yuan DZ, Zhao YB, Nie L, Lei Y,
Liu M, Long Y, Zhang JH, Blok LJ, Burger CW and Yue LM:
Progesterone-induced miR-133a inhibits the proliferation of
endometrial epithelial cells. Acta Physiol (Oxf). 219:683–692.
2017. View Article : Google Scholar
|
|
38
|
Zhao S, Han J, Zheng L, Yang Z, Zhao L and
Lv Y: MicroRNA-203 regulates growth and metastasis of breast
cancer. Cell Physiol Biochem. 37:35–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
